As Part of President Biden’s Unity Agenda, Cancer Moonshot Announces Launch of New ARPA-H Program to Develop Novel Technologies for More Precise and Accurate Cancer Tumor Removal

Program launch represents major milestone for new agency established and funded by President Biden and bipartisan members of Congress to revolutionize how we improve health outcomes for Americans facing cancer and other diseases

President’s Unity Agenda also delivering progress in fight against cancer thanks to the Bipartisan Honoring our PACT Act and SERVICE Act, with new steps from the Department of Veterans Affairs, including to expand access to breast cancer screenings

Today, the Biden Cancer Moonshot announced a first-of-its-kind Advanced Research Projects Agency for Health (ARPA-H) program to develop novel technologies that will allow surgeons to remove cancerous tumors with more precision and accuracy, resulting in better health outcomes for Americans facing cancer. The launch of this program—ARPA-H’s first program targeting cancer and second program overall—represents a major milestone for ARPA-H, the new agency President Biden established and funded with Democrats and Republicans in Congress last year to generate breakthroughs in ways to prevent, detect, and treat cancer and other diseases.

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS